FDA Found Mold at One Chinese GLP-1 Ingredient Plant and Relabeled Ingredients at Another. What It Means for Your Compounded Medication
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you take a compounded GLP-1, last week's news may have made you look twice at your vial. FDA inspectors reported black mold and bugs at one plant in China. At another, staff put their own approval seal on ingredients made elsewhere. Both made raw ingredients for compounded GLP-1 and GLP-1/GIP products (Bloomberg). No report so far ties either plant to a US pharmacy, but the findings point to a question you can ask yours: who made the raw drug in your vial?
Who This Helps
This is for anyone on a compounded GLP-1, or thinking about one, who wants to make sense of the news without panic. It's also for anyone who wants to ask their pharmacy where the drug in their vial comes from.
What the inspectors found
Bloomberg got the FDA's reports through a public records request and wrote about them on October 15 (Bloomberg). NewsNation laid out what was found at each site:
- The Chengdu plant, checked in August: mold on the machines (Briefs), dirty floors and lots of bugs in the ceilings. Staff were seen stuffing lab papers into lockers, and workers poured product samples down sinks in what looked like a coordinated effort (NewsNation).
- The Nanjing plant, checked in September: workers bought raw compounding ingredients made at other plants and put their own seal of approval on them without reviewing the other makers' test data (NewsNation).
The FDA had last checked the Nanjing site in March 2025 and the Chengdu site in September 2023 (NewsNation). Michael Rogers, a former FDA associate commissioner for inspections and investigations who now works as a consultant, said the findings suggest "a serious accident waiting to happen" (Briefs).
What the FDA has already done
Both plants are now on an FDA import alert, which flags the agency to stop their goods at the border (NewsNation). In a stock filing, the Chengdu plant's parent company said the FDA put it on Import Alert 66-40 on September 19, after the visit ended with eight written problems (Tiger Brokers). That alert covers drug makers that haven't met the FDA's factory rules (FDA). We couldn't confirm which alert covers the Nanjing plant. The Chengdu company said it was working to fix the problems (Briefs).
Separately, in 2025 the FDA started a "green list" of GLP-1 raw drug makers it has checked (APC). It can hold shipments from makers that aren't on it (FDA). After inspecting or reviewing records from 48 GLP-1 raw drug sites, the FDA found about 21% weren't up to standard. Some had factory problems, and some didn't answer the FDA's requests for records. It said that during the shortage years the raw drug came from China, India, Europe and elsewhere (FDA). We couldn't tell from the FDA's page whether either plant was ever on the list.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
What we don't know yet
None of the reports we read named which US pharmacies, if any, bought from these two plants. We also didn't find a recall, FDA advice to patients, or reports of anyone harmed. The findings are about the state of the plants and their records, not tests on drugs that reached patients. They are inspection observations, not final FDA rulings, and in its September filing the Chengdu company said it had not received a warning letter.
This isn't only a gray-market story. Bloomberg described both plants as suppliers of active ingredients for compounded GLP-1s, and the FDA spot-checks suppliers to compounding facilities, which must buy from FDA-registered makers (Briefs). The Chengdu plant also holds active US drug master files for its GLP-1 ingredients, which are the FDA filings that buyers in the regulated market rely on (VCBeat). US sales made up about a third of its revenue in the first half of 2026, and after the import alert it said it would stop shipping peptide ingredients to the US (BigGo Finance). So the findings could reach the supply that licensed pharmacies draw on, even though no report has named a US pharmacy that bought from either plant. An import alert stops future shipments at the border, but it doesn't pull back ingredients that arrived earlier.
The FDA says side effects from compounded GLP-1s are likely underreported, partly because federal law doesn't require 503A pharmacies to report them (FDA). It also notes that 503A compounding pharmacies don't have to follow the factory rules raw drug makers do (state pharmacy boards oversee them instead), which raises the risk that a problem with the raw drug isn't caught (FDA).
How licensed pharmacies are supposed to source
By law, the raw drug a compounding pharmacy uses must come from a maker that's registered with the FDA. It must also come with a lab report on that batch, called a certificate of analysis (FDA). A trade group for compounding pharmacies told the FDA this year that licensed pharmacies don't buy from unknown online sellers. It said they buy through FDA-registered, inspected sources, often with lab reports and outside test data (APC).
A lab report is only as good as the plant behind it, as the Nanjing findings show. That's the same gap we wrote about in our guide to lab reports and licenses. The FDA has also proposed limits on where large compounders can get these raw drugs, which we covered here.
Seven checks before you choose a provider
Our guide to the seven checks for choosing a GLP-1 provider covers what to verify before you sign up, including where your ingredient comes from.
If you ever have a reaction you're worried about, tell your prescriber and report it to the FDA through MedWatch (FDA).
Final Takeaway
FDA inspectors found mold and bugs at one Chinese plant and relabeled ingredients at another, both making raw ingredients for compounded GLP-1s, and both are now on import alert. As of October 20, we found no reports naming US pharmacy buyers, no recall and no reports of harm to patients. A compounded shot is only as good as its raw drug, so ask your pharmacy who made yours and whether that maker is on the FDA's green list.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Is my compounded GLP-1 contaminated?
We've found no report that it is. The FDA's findings were about conditions at two plants, and as of October 20 we found no reports naming US pharmacy buyers, recalls or patient harm tied to them. Ask your pharmacy who made the ingredient in your vial.
Do compounded GLP-1 ingredients come from China?
Some do. The FDA says GLP-1 ingredients come from makers around the world, including China, India and Europe, and it keeps a green list of makers it has checked.
Are brand-name GLP-1 shots affected?
None of the reports we read tied these plants to brand-name GLP-1 medicines. Bloomberg described them as makers of compounding ingredients.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
UK officials seized 12,000 fake GLP-1 pens. See where fakes come from, why the US could see more, and how to check the pen in your hand.
Retatrutide isn't approved anywhere, yet it's sold online. See what JAMA found in black market vials and how to spot a safe pharmacy.
FDA's September 2026 warning letter has two separate sets of findings. See which one affects patients and which is a legal dispute.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.